Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
| العنوان: | Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355 |
|---|---|
| المؤلفون: | Schmid, Peter, Cescon, David W., Rugo, Hope S., Im, Seock-Ah, Yusof, Mastura Md, Gallardo, Carlos, Lipatov, Oleg |
| بيانات النشر: | Oxford Univ Press Inc |
| سنة النشر: | 2023 |
| المجموعة: | Ege University Institutional Repository |
| مصطلحات موضوعية: | Double-Blind, European-Organization, Paclitaxel, Atezolizumab, Carboplatin, Society, Impact, Trial |
| الوصف: | Background In KEYNOTE-355 (NCT02819518), the addition of pembrolizumab to chemotherapy led to statistically significant improvements in progression-free survival and overall survival in patients with advanced triple-negative breast cancer with tumor programmed cell death ligand 1 (PD-L1) combined positive score of at least 10. We report patient-reported outcomes from KEYNOTE-355.Methods Patients were randomly assigned 2:1 to pembrolizumab 200 mg or placebo every 3 weeks for up to 35 cycles plus investigator's choice chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin). The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30), Breast Cancer-Specific Quality of Life Questionnaire, and EuroQol 5-Dimension questionnaire visual analog scale were prespecified. Patient-reported outcomes were analyzed for patients who received at least 1 dose of study treatment and completed at least 1 patient-reported outcome assessment. Changes in patient-reported outcome scores from baseline were assessed at week 15 (latest time point at which completion and compliance rates were at least 60% and at least 80%, respectively). Time to deterioration in patient-reported outcomes was defined as time to first onset of at least a 10-point worsening in score from baseline.Results Patient-reported outcome analyses included 317 patients with tumor PD-L1 combined positive score of at least 10 (pembrolizumab plus chemotherapy: n = 217; placebo plus chemotherapy: n = 100). There were no between-group differences in change from baseline to week 15 in QLQ-C30 global health status/quality of life (QOL; least-squares mean difference = -1.81, 95% confidence interval [CI] = -6.92 to 3.30), emotional functioning (least-squares mean difference = -1.43, 95% CI = -7.03 to 4.16), physical functioning (least-squares mean difference = -1.05, 95% CI = -6.59 to 4.50), or EuroQol 5-Dimension questionnaire visual analog scale (least-squares mean difference = 0.18, 95% CI = -5.04 to 5.39) ... |
| نوع الوثيقة: | other/unknown material |
| اللغة: | English |
| تدمد: | 1460-2105 0027-8874 |
| العلاقة: | Jnci-Journal of The National Cancer Institute; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11454/93005Test; https://doi.org/10.1093/jnci/djad240Test; Iwata, Hiroji/0000-0002-0242-4718 |
| DOI: | 10.1093/jnci/djad240 |
| الإتاحة: | https://doi.org/10.1093/jnci/djad240Test https://hdl.handle.net/11454/93005Test |
| حقوق: | none |
| رقم الانضمام: | edsbas.88668889 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 14602105 00278874 |
|---|---|
| DOI: | 10.1093/jnci/djad240 |